Results 111 to 120 of about 10,664 (186)

Canakinumab for Atherosclerotic Disease [PDF]

New England Journal of Medicine, 2018
Rothman, A.M., Morton, A., Crossman, D.
openaire   +11 more sources

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

, 2020
Objectives Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
Marianna Sirico
core  

Pharmacokinetic and Pharmacodynamic Characteristics of Single-dose Canakinumab in Patients With Type 2 Diabetes Mellitus

, 2014
PurposeInterleukin (IL)-1β, an inflammatory molecule, contributes to the development of atherothrombosis and worsening of islet β-cell function. Canakinumab, a human monoclonal antibody, targets IL-1β–dependent inflammation and reduces the vascular ...
Noe, Adele, Skerjanec, A, Howard, Campbell, Thuren, T, Thuren, Tom, Taylor, Ann, Skerjanec, Andrej, Noe, A, Howard, C, Taylor, A   +9 more
core   +1 more source

Muckle-Wells Syndrome Effectively Treated with Canakinumab: Is the Recommended Dosing Schedule Mandatory?

, 2011
Cryopyrin-associated periodic fever syndrome (CAPS) is a rare inherited disease due to mutations in the NLRP3 (also called CIAS1) gene on chromosome 1q44 resulting in overproduction of interleukin-1.
Simon M. Mueller, Peter Itin, Peter Haeusermann   +2 more
core   +1 more source

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

, 2016
OBJECTIVE: In pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis (JIA), but reported adverse events have included macrophage activation syndrome (MAS). This study was undertaken to assess
Grom, Alexei A, Norman T. Ilowite, Ruperto, Nicolino, Grom, Alexei A., Virginia Pascual, Abrams, Ken, Brunner, Hermine I., Paedeatric Rheumotology International Trials Organisation and Paediatric Rheumatology Collaborative Study Group, Ken Abrams, Alberto Martini, Ilowite, Norman T., Daniel Lovell, Martini, Alberto, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Pascual, Virginia, Nicolino Ruperto, Karolynn Leon, Leon, Karolynn, Karine Lheritier, Hermine I. Brunner, Brunner, Hermine I, Wouters, Carine, Lovell, Daniel, Lauwerys, Bernard, Alexei A. Grom, Lheritier, Karine, Ilowite, Norman T   +26 more
core   +1 more source

Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade

JACC: Advances
Background: Serum urate (SU) associates with cardiovascular (CV) events, mortality, and gout. Objectives: The purpose of this study was to assess whether SU predicts CV risk in a trial of interleukin (IL)-1β inhibition with canakinumab, and whether IL-1β
Nicholas H. Adamstein, MD, Jean G. MacFadyen, BA, Brittany N. Weber, MD, PhD, Peter Libby, MD, Daniel H. Solomon, MD, MPH, Paul M Ridker, MD, MPH   +5 more
doaj   +1 more source

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome

, 2018
Objective To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS).
Abrams, Ken, Lachmann, Helen, Letzkus, Martin, Obici, Laura, Tormey, Vincent, Starck-Schwertz, Sandrine, Caorsi, Roberta, Gattorno, Marco, Hartmann, Nicole, Torene, Rebecca, Nirmala, Nanguneri, Cattalini, Marco   +11 more
core  

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Kawasaki disease complicated by macrophage activation syndrome treated with canakinumab. [PDF]

J Hum Immun
Netea SA, van Stijn D, Gruppen MP, van den Berg JM, Blom NA, Kuipers IM, Kuijpers TW.   +6 more
europepmc   +1 more source

Canakinumab vs triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in "difficult to treat" gouty arthritis

, 2010
Monosodium urate crystal deposition seen in gout stimulates IL-1 beta OR IL-1_; release. Canakinumab, a long-acting, fully human anti- IL-1 beta OR IL-1_; monoclonal antibody, effectively neutralizes IL-1 beta OR IL-1_;. Methods: This was an 8-week, dose-
Shamim, T., Schlesinger, N., De Meulemeester, M., Richard, D., Pikhlak, A., Murphy, P., Arulmani, U., Sallstig, P., So, A.   +8 more
core